Identification
- Generic Name
- Zinc trihydroxide
- DrugBank Accession Number
- DB02165
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Zinc trihydroxide (DB02165)
- Weight
- Average: 119.43
Monoisotopic: 117.960836 - Chemical Formula
- H6O3Zn
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UGlutathione S-transferase Mu 1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCarbamazepine Zinc trihydroxide can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy. Ceftibuten Zinc trihydroxide can cause a decrease in the absorption of Ceftibuten resulting in a reduced serum concentration and potentially a decrease in efficacy. Cephalexin Zinc trihydroxide can cause a decrease in the absorption of Cephalexin resulting in a reduced serum concentration and potentially a decrease in efficacy. Cinoxacin Zinc trihydroxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Ciprofloxacin Zinc trihydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- JKKHGFKPEJPPQG-UHFFFAOYSA-N
- InChI
- InChI=1S/3H2O.Zn/h3*1H2;
- IUPAC Name
- trihydrate zinc
- SMILES
- [Zn].[H]O[H].[H]O[H].[H]O[H]
References
- General References
- Not Available
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.65 Chemaxon pKa (Strongest Acidic) 15.7 Chemaxon pKa (Strongest Basic) -1.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 25.3 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 3.7 m3·mol-1 Chemaxon Polarizability 1.51 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7517 Blood Brain Barrier + 0.9003 Caco-2 permeable - 0.6944 P-glycoprotein substrate Non-substrate 0.8642 P-glycoprotein inhibitor I Non-inhibitor 0.9819 P-glycoprotein inhibitor II Non-inhibitor 0.9934 Renal organic cation transporter Non-inhibitor 0.948 CYP450 2C9 substrate Non-substrate 0.8115 CYP450 2D6 substrate Non-substrate 0.8421 CYP450 3A4 substrate Non-substrate 0.7713 CYP450 1A2 substrate Non-inhibitor 0.8883 CYP450 2C9 inhibitor Non-inhibitor 0.8809 CYP450 2D6 inhibitor Non-inhibitor 0.9169 CYP450 2C19 inhibitor Non-inhibitor 0.8957 CYP450 3A4 inhibitor Non-inhibitor 0.9669 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9719 Ames test Non AMES toxic 0.839 Carcinogenicity Carcinogens 0.632 Biodegradation Ready biodegradable 0.6063 Rat acute toxicity 1.8653 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8102 hERG inhibition (predictor II) Non-inhibitor 0.9574
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein homodimerization activity
- Specific Function
- Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
- Gene Name
- GSTM1
- Uniprot ID
- P09488
- Uniprot Name
- Glutathione S-transferase Mu 1
- Molecular Weight
- 25711.555 Da
References
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52